ST2-104 decreases the Aβ_25-35-mediated increase in intracellular Ca²⁺. by Yingshi Ji (9013004)

Ofd1 protection of photoreceptors from oxidative stress via decreasing ROS production. by Juan Wang (115708)

“…(C) These results showed that the SOD and CAT activities decreased by 40% and 30% in MNU-treated cells (MNU), but was partially attenuated by Ofd1 overexpression (Ofd1-CDS+MNU). …”

Decreased oscillatory flow decreases <i>klf2a</i> expression. by Julien Vermot (257990)

“…(G) <i>klf2a</i> expression decreases after 15-h lidocaine treatment (90%, <i>n</i> = 67). …”

Reduced follicles, decreased ovulation and decreased fertilization of female Meox-2-cre/Separase S1121A mutant mice. by Juan Xu (225010)

Damsin (D) and ambrosin (A) treatment decreases the CSC population. by Wendy Soria Sotillo (4408105)

C2GnT1 gene knockdown decreases C2-O-sLe^X glycoproteins and C2GnT1 activity. by Catherine A. St. Hill (357388)

Subjects:

The decrease in blood flow disrupts CV pruning. by Lin Wen (557398)

SDG decreases iron-induced apoptosis in H9c2 cells. by Stephanie Puukila (568109)

Decreasing pixel differences caused by worm movement correspond to decreasing locomotive health. by Areta Jushaj (8525655)

SDG decreases iron-induced oxidative stress in H9c2 cells. by Stephanie Puukila (568109)

of decreased GFR by age and gender. by Hui Song (53547)

Subjects:

YTX treatment decreases tumour development in the B16F10 melanoma mouse model. by Araceli Tobío (3545306)

Resveratrol decreases PKM2 expression. by Mohd Askandar Iqbal (324124)

Subjects:

Pretreatment with SDG prevents iron induced decrease in H9c2 cell size. by Stephanie Puukila (568109)

SDG decreases iron-induced MMP gene expression in H9c2 cells. by Stephanie Puukila (568109)

Probability of release is decreased by hydrophobic mutations. by Matthew R. Bowers (8423115)

Decreasing cell adhesion decreases [Ca²⁺]_i oscillation frequency. by Charles Godbout (540424)

Silencing of Rap1A decreases ERK and p38 activation. by Yougen Wu (830191)

GSK343 decreased tumor stemness. by Laura V. Bownes (10276762)

Subjects:

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”